TMDX vs. ITGR, LIVN, MASI, CNMD, INMD, SLNO, NUVL, DOCS, IMVT, and SEM
Should you be buying TransMedics Group stock or one of its competitors? The main competitors of TransMedics Group include Integer (ITGR), LivaNova (LIVN), Masimo (MASI), CONMED (CNMD), InMode (INMD), Soleno Therapeutics (SLNO), Nuvalent (NUVL), Doximity (DOCS), Immunovant (IMVT), and Select Medical (SEM). These companies are all part of the "medical" sector.
TransMedics Group (NASDAQ:TMDX) and Integer (NYSE:ITGR) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, community ranking, media sentiment, dividends, valuation, analyst recommendations and profitability.
Integer has a net margin of 6.01% compared to TransMedics Group's net margin of -3.43%. Integer's return on equity of 11.25% beat TransMedics Group's return on equity.
In the previous week, Integer had 9 more articles in the media than TransMedics Group. MarketBeat recorded 18 mentions for Integer and 9 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 0.78 beat Integer's score of 0.65 indicating that TransMedics Group is being referred to more favorably in the media.
TransMedics Group presently has a consensus target price of $119.00, suggesting a potential downside of 13.76%. Integer has a consensus target price of $128.67, suggesting a potential upside of 6.41%. Given Integer's higher possible upside, analysts plainly believe Integer is more favorable than TransMedics Group.
TransMedics Group has a beta of 1.87, suggesting that its share price is 87% more volatile than the S&P 500. Comparatively, Integer has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500.
Integer received 290 more outperform votes than TransMedics Group when rated by MarketBeat users. Likewise, 63.51% of users gave Integer an outperform vote while only 54.78% of users gave TransMedics Group an outperform vote.
Integer has higher revenue and earnings than TransMedics Group. TransMedics Group is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.
99.7% of TransMedics Group shares are owned by institutional investors. Comparatively, 99.3% of Integer shares are owned by institutional investors. 7.0% of TransMedics Group shares are owned by insiders. Comparatively, 2.0% of Integer shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Integer beats TransMedics Group on 11 of the 18 factors compared between the two stocks.
Get TransMedics Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for TMDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TMDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
TransMedics Group Competitors List
Related Companies and Tools